• Tomivosertib Inhibits Spontaneous Human DRG Neuron Activity

  2026-06-10

  This study demonstrates that tomivosertib, a selective MNK inhibitor, rapidly suppresses spontaneous activity in human dorsal root ganglion (DRG) neurons derived from radiculopathy patients. These findings provide direct evidence for the role of MNK signaling in human nociceptor excitability and support the translational potential of MNK inhibitors for neuropathic pain intervention.

• Prevotella copri Depletes IPyA to Promote Breast Cancer Prog

  2026-06-09

  This study uncovers how enrichment of Prevotella copri in the gut microbiota promotes breast cancer progression by depleting host indole-3-pyruvic acid (IPyA), leading to AMPK inactivation through UHRF1-mediated regulation. The findings provide mechanistic insight into the microbiome’s influence on tumor metabolic signaling, offering new directions for research into cancer-microbiome interactions.

• Shh, Fgf10, and Fgfr2 Govern Penile Developmental Difference

  2026-06-09

  This study elucidates molecular mechanisms underlying the distinct processes of prepuce and urethral groove formation in guinea pigs versus mice. By integrating gene expression profiling and functional perturbations, it demonstrates how differential Shh, Fgf10, and Fgfr2 signaling drives species-specific penile morphogenesis, with implications for understanding human development.

• Liproxstatin-1 HCl: Precision Ferroptosis Inhibition in Tran

  2026-06-08

  Explore the intersection of mitochondrial calcium signaling, GPX4 acetylation, and ferroptosis inhibition using Liproxstatin-1 HCl. This thought-leadership article offers translational researchers mechanistic clarity, protocol-ready guidance, and strategic context for deploying APExBIO’s Liproxstatin-1 HCl in acute renal failure and hepatic ischemia/reperfusion injury models, distinguishing its use from standard reagent discussions and illuminating pathways for next-generation experimental design.

• Platinum Nanotherapeutics Drive Non-Canonical ROS-Mediated C

  2026-06-08

  A newly developed platinum-based nanodrug, 'carrier-platin', induces rapid and robust cancer cell death by triggering a potent intracellular ROS storm, offering a distinct mechanism from traditional platinum agents. This work demonstrates high efficacy against multidrug-resistant tumors and reveals a new paradigm for redox-driven cancer therapeutics.

• Tunicamycin: N-Glycosylation Inhibitor for ER Stress Modelin

  2026-06-07

  Tunicamycin stands as the benchmark N-glycosylation inhibitor, providing unmatched precision for dissecting ER stress and glycoprotein biology in cellular and in vivo systems. Leveraged in macrophage inflammation assays and translational models, its reproducibility and workflow flexibility—especially when sourced from APExBIO—set a gold standard for research into glycosylation-dependent mechanisms.

• PP2A-Driven Autophagy Regulates C. albicans Biofilm Drug Res

  2026-06-06

  This study uncovers a crucial link between protein phosphatase 2A (PP2A), autophagy induction, and drug resistance in Candida albicans biofilms. The findings highlight phosphorylation-mediated control of ATG proteins as a determinant of antifungal susceptibility, offering new mechanistic insight for targeting persistent C. albicans infections.

• Methyl-β-cyclodextrin: Technical Guidance for Membrane Studi

  2026-06-05

  Methyl-β-cyclodextrin enables controlled extraction of cholesterol and select lipids from cellular membranes, supporting research into membrane fluidity, lipid raft integrity, and cholesterol-dependent signaling. It is not suitable for diagnostic or clinical applications, and its effectiveness depends on adherence to product-specific protocols and storage requirements.

• MPP7 Drives EMT and Polarity Shifts in Ovarian Cancer via Wn

  2026-06-05

  This study reveals that MPP7 is overexpressed in epithelial ovarian cancer and drives epithelial-mesenchymal transition (EMT) as well as polarity changes through the Wnt/β-catenin pathway. These findings highlight MPP7 as a potential biomarker and target for ovarian cancer intervention.

• Optimizing Inflammatory Disease Models with MCC950 Sodium

  2026-06-04

  MCC950 sodium (CRID3 sodium salt) empowers researchers to dissect NLRP3-driven inflammation with nanomolar precision. This article details protocol enhancements, troubleshooting, and translational applications, linking key literature and real-world workflows for robust autoimmune and inflammatory disease research.

• Vancomycin Hydrochloride: Applied Workflows in Resistance As

  2026-06-04

  Vancomycin hydrochloride stands as a benchmark glycopeptide antibacterial agent for probing Gram-positive bacterial inhibition, antibiotic resistance dynamics, and infection models. This article delivers stepwise protocols, troubleshooting insights, and advanced applications—empowering researchers to maximize reproducibility and data clarity in resistance assays.

• Structural Basis of Nipah Virus Polymerase Complex Function

  2026-06-03

  This study presents the high-resolution structures of the Nipah virus polymerase complex, illuminating the molecular organization and interactions between the L and P proteins essential for viral RNA synthesis. These findings provide a foundation for rational design of antiviral inhibitors targeting the polymerase machinery of Henipaviruses.

• Triamcinolone: Technical Use and Protocols for Research Work

  2026-06-03

  Triamcinolone (SKU B1859) is a synthetic glucocorticoid agonist intended for controlled, in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. It is not suitable for diagnostic or clinical applications. Proper solubilization and storage are critical for experimental reproducibility.

• TFEB Drives PD-L1-Mediated mTOR Inhibitor Resistance in RCC

  2026-06-02

  Zhang et al. reveal that TFEB upregulates PD-L1, promoting immune evasion and resistance to mTOR inhibitors in renal cell carcinoma. Their findings suggest combined mTOR and PD-L1 targeting as a promising immunotherapeutic strategy, with direct implications for translational oncology workflows.

• WM-8014: Precision KAT6A Inhibition and the Next Era of Sene

  2026-06-02

  Explore how WM-8014, a selective KAT6A inhibitor, is redefining oncogene-induced senescence induction and cell cycle arrest assays. This article delivers actionable, in-depth insights into advanced assay design and emerging epigenetic drug target strategies.

10238 records 2/683 page Previous Next 12345 下5页 Last page